Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

8973 results about "Drug delivery" patented technology

Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. It may involve scientific site-targeting within the body, or it might involve facilitating systemic pharmacokinetics; in any case, it is typically concerned with both quantity and duration of drug presence. Drug delivery is often approached via a drug's chemical formulation, but it may also involve medical devices or drug-device combination products. Drug delivery is a concept heavily integrated with dosage form and route of administration, the latter sometimes even being considered part of the definition.

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to immediate or sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Audible indicator

The disclosure relates to an audible indicator in combination with a drug delivery device having a resilient force member capable of resting in either of two states. In a biased state, the resilient force member is biased and stores energy and in a relaxed state, the resilient force member is relaxed. The resilient force member releases the stored energy when changing from the biased state into the relaxed state, thereby generating an audible signal, wherein the resilient force member is supported by a retaining element in the biased state in order to prevent transition into the relaxed state.
Owner:SANOFI AVENTIS DEUT GMBH

Audible indicator

The disclosure relates to an audible indicator for use with a drug delivery device comprising a bistable resilient force member capable of residing in two states. In a biased state, the resilient force member is biased and stores energy In a relaxed state, the resilient force member is relaxed. The resilient force member releases the stored energy when transitioning from the biased state into the relaxed state, thereby generating an audible signal.
Owner:SANOFI AVENTIS DEUT GMBH

Drug eluting ocular implant and method of treating an ocular disorder

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Owner:GLAUKOS CORP

Drug eluting ocular implant

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Owner:GLAUKOS CORP

Implants with controlled drug delivery features and methods of using same

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Owner:GLAUKOS CORP

Intraocular drug delivery platform

An intraocular drug delivery platform including a ring having an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass operably coupled to the anterior surface of the ring, and a second drug eluting mass operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO +1

Tandem, with adjustable glucose boundaries based on activity and / or sleep

Systems and methods for integrating a continuous glucose sensor 12, including a receiver 14, a medicament delivery device 16, a controller module, and optionally a single point glucose monitor 18 are provided. Integration may be manual, semi-automated and / or fully automated.
Owner:DEXCOM INC

Implants with controlled drug delivery features and methods of using same

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Owner:GLAUKOS CORP

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Method and system for identifying biological entities for drug discovery

A computer-implemented method of training a machine learning model to identify biological entities for drug discovery is disclosed. The method comprises providing a training data set comprising a plurality of entity-linked text sequences, each text sequence including a mention of a biological entity, where the biological entity is linked to a corresponding biological entity identifier from a set of possible biological entity identifiers; masking the mention of the biological entity within each text sequence; encoding each masked text sequence into an input representation for a machine learning model; and training a machine learning model to predict the unique entity identifier of the masked biological entity based on the input representation. The described method is able to utilise the full breadth of the rich contextual information available in the biomedical text corpus to predict new biological targets for drug discovery and avoids the restrictions intrinsic to relationship prediction using knowledge graphs. The ability to identify more promising, biologically relevant targets in an automated manner, significantly reduces the requirement of human input and reduces the failure rate in targets that are progressed in the drug delivery pipeline.
Owner:BENEVOLENTAI TECH LTD

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Near-infrared emission aggregation-induced emission organic photo-thermal molecule as well as preparation method and application thereof

The invention discloses a near-infrared emission aggregation-induced emission organic photo-thermal molecule and a preparation method and application thereof, and belongs to the technical field of biomedicine, and the structure is shown as a formula I: # imgabs0 # (I), wherein R1, R2, R3, R4, R5 and R6 are independently selected from groups containing alkyl chains. The invention also provides a preparation method of the organic photo-thermal molecule and application of the organic photo-thermal molecule in preparation of multifunctional protein nanoparticles with near-infrared aggregation-induced emission. The near-infrared emission aggregation-induced emission organic photo-thermal molecule provided by the invention shows excellent near-infrared imaging effect and photo-thermal capability under laser irradiation, and the obtained near-infrared aggregation-induced emission multifunctional protein nano particle has excellent photo-thermal effect and imaging resolution, has excellent targeting to brain tumor, and has good application prospects in blood brain barrier crossing, brain tumor targeting and brain tumor targeting. And tumor killing, photothermal and ferroptosis combined treatment has practical medical significance, and is expected to be widely applied to the aspects of intelligent drug delivery and nano medical treatment.
Owner:THE CHINESE UNIV OF HONG KONG (SHENZHEN)

Pharmaceutical composition comprising adrenaline

ActiveUS20250041243A1Organic active ingredientsDigestive systemEpinephrine adrenalineBULK ACTIVE INGREDIENT
Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of:a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; anda pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15.Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
Owner:OREXO AB

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Drug delivery device

A drug delivery device may include a housing having an opening and a drug storage container having a body portion with a proximal end and a distal end and a delivery member extending from the distal end of the body portion. The device may also include a plunger moveable toward the distal end of the drug storage container to expel a drug from the drug storage container through the delivery member and a plunger biasing member configured to urge the plunger toward the distal end of the drug storage container. The device may further include a container holder configured to support the drug storage container with respect to the housing such that a resultant force acting on the drug storage container from the plunger biasing member is at least substantially completely borne by the distal end of the body portion of the drug storage container.
Owner:AMGEN INC

Sub-assembly for a medicament delivery device

The present disclosure provides a sub-assembly for a medicament delivery device. The sub-assembly includes a housing and a delivery member cover arranged in the housing and configured to move axially in the housing from an extended position towards a retracted position. The delivery member cover includes a radial wall provided with an axial through-opening. The sub-assembly further includes a removable cap assembly. The removable cap assembly includes a cap configured to be fitted to the delivery member cover and / or to the housing, a distal cap end, and a delivery member shield gripping sleeve having a radially flexible axially extending arm.
Owner:SHL MEDICAL AG

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Implants with controlled drug delivery features and methods of using same

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Owner:GLAUKOS CORP

Drug delivery device with feedback mechanism

The disclosure relates to a drug delivery device comprising:a case adapted to hold a medicament container,a plunger disposed within the case and slidable from a proximal position into a distal position for delivering a medicament from the medicament container,at least one feedback mechanism that is in operative connection with the plunger, the feedback mechanism comprising a collar, a control spring biasing the collar in a distal direction, a needle shroud, operatively axially abutting the collar in a first coupled state and prevented from axially decoupling the collar by the plunger in its proximal position, wherein the plunger, when approaching the distal position during movement from the proximal position towards the distal position, is adapted to allow axial decoupling of the needle shroud from the collar, thus allowing for a limited axial movement of the collar relative to the needle shroud until the collar axially abuts the needle shroud in a second coupled state.
Owner:SANOFI AVENTIS DEUT GMBH

Remote dosing control system for operation of steam boiler

The invention relates to the technical field of remote control, in particular to a steam boiler operation remote dosing control system which comprises a multi-source acquisition module, a state judgment module, a path switching module, a quality verification module and a health evolution module. According to the method, a monitoring system is constructed by fusing multi-dimensional parameters such as flow, pressure and temperature in real time, a single sensor error is eliminated through Kalman filtering, a heat transfer correlation model is established to quantify the water quality and thermal coupling relation, a pipeline blockage critical point is pre-judged based on grey correlation analysis, and non-inductive switching of a dosing path is achieved by adopting a double-electromagnetic-valve redundancy architecture. The stability of medicament conveying is verified by combining the flow offset of a standby path, closed-loop comparison of a concentration amplification value and a target value is synchronously executed to trigger self-calibration to correct the feeding deviation, a water quality adjustment-path switching-precision verification linkage control chain is formed, the abnormal response period is shortened, the scaling rate of a heat transfer surface is reduced, and the stability of the heat efficiency of the boiler is maintained. The equipment maintenance period is prolonged.
Owner:QUANZHOU BRANCH OF FUJIAN SPECIAL EQUIP INSPECTION & RES INST

Implants with controlled drug delivery features and methods of using same

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Owner:GLAUKOS CORP

Immune microbubble complex and its uses

The present invention relates to an immunomicrobubble complex and its uses. The immunomicrobubble complex (IMC) according to the present invention comprises microbubbles conjugated with an antibody, wherein the microbubbles have excellent stability and excellent antibody binding strength, and it has been confirmed that when the immunomicrobubble complex is treated with high-intensity focused ultrasound (HIFU), the anti-tumor effect is significantly enhanced and an immune-enhancing effect is exhibited. Therefore, the immunomicrobubble complex according to the present invention is expected to improve the delivery efficiency of the conjugated antibody and can be used for the diagnosis and treatment of cancer, and exhibits various functions in the field of immunotherapy, including a contrast effect, improvement of half-life, improvement of drug delivery, lymphocyte concentrating effect, cancer immunotherapy, and ultrasound-induced immunotherapy.
Owner:IMGT

Bioresorbable ocular drug delivery device

Disclosed herein are implantable intraocular drug delivery devices structured to provide targeted and / or controlled release of a drug to a desired intraocular target tissue, and methods of implanting and methods of using such devices for the treatment of ocular diseases and disorders. In certain embodiments, some, most, or essentially all of the device is made of biodegradable materials.
Owner:GLAUKOS CORP

Drug delivery device with feedback mechanism

The disclosure relates to a drug delivery device comprising:a case adapted to hold a medicament container,a plunger disposed within the case and slidable from a proximal position into a distal position for delivering a medicament from the medicament container,at least one feedback mechanism that is in operative connection with the plunger, the feedback mechanism comprising a collar, a control spring biasing the collar in a distal direction, a needle shroud, operatively axially abutting the collar in a first coupled state and prevented from axially decoupling the collar by the plunger in its proximal position, wherein the plunger, when approaching the distal position during movement from the proximal position towards the distal position, is adapted to allow axial decoupling of the needle shroud from the collar, thus allowing for a limited axial movement of the collar relative to the needle shroud until the collar axially abuts the needle shroud in a second coupled state.
Owner:SANOFI AVENTIS DEUT GMBH

Implants with controlled drug delivery features and methods of using same

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Owner:GLAUKOS CORP